Eikon Therapeutics Draws Buy Ratings from Morgan Stanley, JPMorgan, and Mizuho

Wall Street initiates coverage on Eikon Therapeutics with Overweight/Outperform ratings and price targets of $26–$32 (vs ~$13.78 current price). Bullish on oncology pipeline, innovative microscopy tech, and 2026 data catalysts.